NEW YORK (GenomeWeb News) — Fluidigm reported after the market closed on Wednesday that its third quarter revenues increased 43 percent year over year, driven by growth in both consumables and instrumentation, and particularly by single-cell genomics applications.

The firm's shares spiked in Thursday morning trade on the Nasdaq, rising 18 percent to $30.00.

For the three months ended September 30, total revenues were $18.3 million compared to $12.8 million for the third quarter of 2012, and beating the average Wall Street estimate of $16.7 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more. 

May
01
Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.